Market Signal Briefing

Key Takeaways CRWV has transformed from crypto miner to an AI infrastructure powerhouse.The company will report earnings on Monday, November 9th. Is soaring AI demand sustainable?
CoreWeave Right Place at the Right TimeFounded by three former commodities traders in New Jersey, ‘Atlantic Crypto’ first opened up shop as a crypto mining company, leveraging its graphic processing units (GPUs) to earn crypto rewards. At the time, crypto was becoming mainstream, Bitcoin was on its way to ~20x gains in two years, and business was good. However, in 2018, fate intervened when the crypto markets crashed and Bitcoin fell 80% from its peak.

CoreWeave Pivots from Crypto Mining to AIWhile it didn’t seem like it at the time, the crypto crash would ultimately prove to be the best possible outcome for the company. Instead of fighting a brutal crypto bear market, the Atlantic Crypto team pivoted, sensing the incoming AI revolution. In 2019, the company changed its name to CoreWeave ((CRWV - Free Report) ). What happened next was an incredible stroke of luck, coupled with foresight.

CoreWeave had exactly the right ingredients to pivot into an AI juggernaut, including multiple data centers and the hard-to-get and highly coveted Nvidia ((NVDA - Free Report) ) H100 chips. Between a unique agreement with Nvidia and its existing data center infrastructure, CoreWeave began providing cloud computing infrastructure necessary to train large language models (LLMs) to big tech companies, just as the AI race heated up and billions in CAPEX would be spent. Meanwhile, as an early mover, CoreWeave has optimized its platform to meet specialized AI needs, offering industry-best performance at a fraction of the price.

CoreWeave Earnings Preview·       When: On Monday, November 10th, CoreWeave will report its third earnings results as a public company after the US equity market closes.

·       Wall Street Expectations: Zacks Consensus Estimates suggest revenue of $1.28B and EPS of  $-0.39.

·       Expected Move: Because CRWV is a volatile, relatively new stock, the earnings move is expected to be large. The options market is implying a ~18% move post-EPS.

Is AI Spend Sustainable?Heading into CRWV EPS, one big question mark for the company is how sustainable the massive CAPEX AI spending will be. Earlier this month, the sustainability came into question when OpenAI CEO Sam Altman took offense to a question from investor Brad Gerstner, who asked, “How can a company with $13 billion in revenues make $1.4 trillion of spend commitments?” Meanwhile, Meta Platforms ((META - Free Report) ), one of the biggest spenders, recently secured $30 billion in private financing for its latest data center investments. Over the past few quarters, CRWV has won multi-billion-dollar contracts from each company.

Bottom line

CoreWeave has transformed from a crypto miner to one of the most critical infrastructure providers in the AI boom. With demand for AI compute accelerating, CRWV’s earnings will be among the closely watched reports on Wall Street.

Gold edged higher in early Asian trade amid signs of U.S. economic weakness which typically enhance the safe-haven allure of the precious metal.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of CarMax, Inc. (NYSE: KMX) between June 20, 2025 and November 5, 2025, both dates inclusive (the "Class Period"). The Class Period was expanded to include more investors. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2026 in the securities class action first filed by the Firm.

So what: If you purchased CarMax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the CarMax class action, go to https://rosenlegal.com/submit-form/?case_id=47077 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants recklessly overstated CarMax's growth prospects when, in reality, its earlier growth in the 2026 fiscal year was a temporary benefit from customers buying cars due to speculation regarding tariffs; and (2) as a result, defendants' statements about CarMax's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the CarMax class action, go to https://rosenlegal.com/submit-form/?case_id=47077 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

, /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fluor Corporation (NYSE: FLR) between February 18, 2025 and July 31, 2025, both dates inclusive (the "Class Period"), of the important November 14, 2025 lead plaintiff deadline.

So what: If you purchased Fluor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Fluor class action, go to https://rosenlegal.com/submit-form/?case_id=44868mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) costs associated with the Gordie Howe International Bridge ("Gordie Howe"), the Interstate 365 Lyndon B. Johnson ("I-635/LBJ") and Interstate 35E ("I-35") highways in Texas projects were growing because of, inter alia, subcontractor design errors, price increases, and scheduling delays; (2) the foregoing, as well as customer reduction in capital spending and client hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on Fluor's business and financial results; (3) accordingly, Fluor's financial guidance for the full year 2025 was unreliable and/or unrealistic, the effectiveness of Fluor's risk mitigation strategy was overstated, and the impact of economic uncertainty on Fluor's business and financial results was understated; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Fluor class action, go to https://rosenlegal.com/submit-form/?case_id=44868 or mailto:call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

By

PYMNTS
 | 
November 9, 2025

 | 

A federal judge has rejected Capital One’s $425 million settlement with depositors.

Those depositors had sued the financial services giant saying they were cheated out of high interest rates, but the judge handling the class action case found that the payout the company had in mind was too small, Reuters reported Friday (Nov. 7).

The settlement had aimed to resolve claims that Capital One kept rates at 0.3% on its “high interest” 360 Savings accounts, while offering higher rates to new customers on similarly named 360 Performance Savings accounts.

Capital One had agreed earlier this year to pay $300 million of unpaid interest to 360 Savings depositors, along with $125 million of interest to customers still holding their accounts.

However, U.S. District Judge David Novak found that the strength of the plaintiffs’ claims justified “significantly greater relief.” He said the deal seemed to give 360 Savings depositors less than 10% of their damages, and left them with the low-yielding accounts while 360 Performance Savings customers earned four to eight times more.

“These millions of class members would continue to experience the same financial harm that they have already experienced for years,” Novak wrote.

Advertisement: Scroll to Continue

According to Reuters, the judge ordered both sides to go back to the negotiating table to  address his concerns. PYMNTS has contacted Capital One for comment but has not yet gotten a reply.

Capital One is also facing a lawsuit over the same issue in New York state, where Attorney General Letitia James has alleged that the company misled customers about the existence of its higher interest savings account.

Capital One has said that it “strongly” disagrees with the attorney general’s claims and will “vigorously defend” itself in court.

“Our flagship 360 Performance Savings product was marketed widely, including on national television, and has always been available in just minutes to all new and existing customers without any of the usual industry restrictions,” the company told PYMNTS in May.

The legal battle comes at a time when savings has “become both a goal and a defense mechanism” for younger Americans, as PYMNTS wrote last month. Research from PYMNTS Intelligence finds that members of Generation Z are saving at higher rates than their older counterparts, even if the total amounts are smaller.

Roughly 80% of Gen Z consumers say they keep some money in savings accounts or cash reserves, compared to 73% of millennials and a little more than 60% of Gen X consumers.

“Yet, the buffer they’re able to build is thin,” PYMNTS wrote. “Most keep less than three months’ worth of expenses on hand, reflecting the precarious balance between ambition and affordability.”

Picking a small stake in early stage AI infrastructure players can prove a smart move for investors with above-average risk appetite.

Shares of SuperX AI Technology (SUPX 6.50%) have gained over 1,234% so far in 2025. Despite these stellar gains, there is one solid reason the stock of this full-stack artificial intelligence (AI) infrastructure player focused on building data center capacity in the Asia-Pacific market could continue to soar in the coming months.

Modular AI Factory Rollout
SuperX's Modular AI Factory is a unique solution that enables enterprises to build and deploy data centers rapidly. By deploying prefabricated modules that provide compute, cooling, and power services, enterprises can reduce deployment time from an 18- to 24-month construction cycle to less than six months. The speed advantage becomes even more crucial, considering that the explosive demand for data center capacity currently surpasses available supply.

Image source: Getty Images.

Additionally, each module delivers 20-megawatt compute capacity and supports up to 144 of Nvidia's GB200 NVL72 systems (72 Blackwell architecture GPUs connected via NVLink).

Today's Change

(

-6.50

%) $

-3.29

Current Price

$

47.35

In October 2025, SuperX announced an investment in MicroInference, a solution provider in the Nvidia Partner Network, to strengthen the supply chain for Nvidia's servers and networking solutions. The company has also entered into a collaboration with a subsidiary of Shenzhen Chengtian Weiye to jointly develop liquid cooling solutions for AI data centers.

Financial strength and valuation
SuperX exited fiscal 2025 (ending June 30, 2025) with $17.2 million in cash and $52.1 million in assets. The company has secured funding of $70 million from long-term investors since March 2025 and over $170 million from institutional investors in October 2025. Hence, the company has sufficient financial flexibility to continue investing in growth initiatives in the short run.

SuperX trades at a significantly elevated valuation of over 377 times sales. However, this is typical for an early stage AI infrastructure player. SuperX is definitely one of the riskier stocks in the market, due to volatile financials and limited revenue visibility. However, it may be a worthwhile decision for investors with higher-than-average risk appetite to pick up a small stake in this stock.

Manali Pradhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy.

WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.2-4

Baxdrostat met the primary endpoint in the Bax24 Phase III trial, delivering clinically meaningful and consistent blood pressure reductions in patients with treatment-resistant hypertension. At 12 weeks, the placebo-adjusted reduction in ambulatory 24-hour average SBP was 14.0 mmHg (95% confidence interval [CI] -17.2, -10.8; p<0.0001).1 Baxdrostat was generally well tolerated, with a safety profile consistent with the BaxHTN trial.1,5

Baxdrostat demonstrated statistically significant and clinically meaningful reductions in key secondary endpoints, including ambulatory night-time average SBP (13.9 mmHg placebo-adjusted [95% CI -17.5, -10.3; p<0.0001]) and seated SBP (10.3 mmHg placebo-adjusted [95% CI -14.9, -5.6; p<0.0001]) consistent with data from the BaxHTN trial.1,5 Significantly more patients treated with baxdrostat (71%) achieved ambulatory 24-hour average SBP of less than 130 mmHg compared with patients receiving placebo (17%) (Odds ratio 15.2 [95% CI 6.6, 35.2; p<0.0001]).1

Dr. Bryan Williams, Chair of Medicine at University College London, primary investigator, said: “The landmark results from Bax24 Phase III trial demonstrate that patients with the hardest-to-control hypertension treated with baxdrostat achieved a highly clinically meaningful 14 mmHg placebo-adjusted reduction in 24-hour systolic blood pressure, which could transform treatment practice. It's remarkable to see this magnitude of reduction coupled with the fact that just over 70% of baxdrostat patients achieved guideline targets, consistently over 24 hours.”

Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, said: “The Bax24 data demonstrate the significant impact that baxdrostat’s long half-life and highly selective inhibition of aldosterone synthase can have in improving 24-hour and overnight blood pressure for patients with resistant hypertension. Patients with elevated night-time blood pressure are especially vulnerable to cardiovascular events, including heart attack and stroke. Together with the results from BaxHTN, these findings demonstrate the potential of baxdrostat to redefine what is possible for the millions of patients whose hypertension remains uncontrolled despite current therapies.”

There are 1.4 billion people worldwide living with hypertension.6 In the US, approximately 50% of patients living with hypertension on multiple treatments do not have their blood pressure under control.7 Consistent 24-hour blood pressure control is an important clinical outcome in patients with hard-to-control hypertension.8-10 Multiple studies have demonstrated that 24-hour blood pressure is a more powerful predictor of cardiovascular events than a clinic-based measurement.4,11 When 24-hour average systolic blood pressure rises by 9.5 mmHg, the risk of all-cause mortality increases by 30%.4

Full results from the Bax24 trial were presented today at the Emerging Opportunities for Managing Cardiometabolic Syndrome late breaker session at the American Heart Association (AHA) Scientific Sessions 2025. These data will be shared with regulatory authorities around the world.

Baxdrostat is designed to lower blood pressure by specifically inhibiting aldosterone, a key hormone that raises blood pressure and increases the risk of heart and kidney problems. Phase I studies show baxdrostat reached peak levels in the blood within 2 to 4 hours and had a half-life of about 26 to 30 hours.12,13 Baxdrostat is currently being investigated as a monotherapy for hypertension13-16 and primary aldosteronism,17 and in combination with dapagliflozin for chronic kidney disease18,19 and the prevention of heart failure in high-risk patients.20

Primary and secondary endpoints1

Primary endpoint

Comparison with placebo

Measure

Group

n

Estimate

95% CI

Estimate

95% CI

p-value

Change from baseline in average 24-hour SBP (mmHg)*

(LS Means)

Baxdrostat 2 mg (N=108)

89

-16.6

-18.8,

-14.3

-14.0

-17.2,

-10.8

<0.0001

Placebo (N=109)

95

-2.6

-4.7, -0.4

Secondary endpoints

Comparison with placebo

Measure

Group

n

Estimate

95% CI

Estimate

95% CI

p-value

Change from baseline in ambulatory night-time average SBP (mmHg) at Week 12

(LS Means)

Baxdrostat 2 mg (N=108)

89

-16.0

-18.6,

-13.4

-13.9

-17.5,

-10.3

<0.0001

Placebo (N=109)

95

-2.1

-4.6, 0.4

Change from baseline in ambulatory daytime average SBP (mmHg) at Week 12

(LS Means)

Baxdrostat 2 mg (N=108)

89

-16.8

-19.2,

-14.4

-14.1

-17.4,

-10.7

<0.0001

Placebo (N=109)

95

-2.7

-5.1, -0.4

Change from baseline in seated SBP (mmHg) at Week 12

(LS Means)

Baxdrostat 2 mg (N=108)

108

-14.9

-18.2,

-11.6

-10.3

-14.9,

-5.6

<0.0001

Placebo (N=109)

109

-4.7

-7.9, -1.4

Achieving ambulatory 24-hour average SBP of < 130 mmHg at Week 12

(Odds ratio)

Baxdrostat 2 mg (N=108)

85

60 (70.6%)

NA

15.2

6.6, 35.2

<0.0001

Placebo (N=109)

84

14 (16.7%)

NA

Change from baseline in ambulatory 24-hr average DBP (mmHg) at Week 12

(LS Means)

Baxdrostat 2 mg (N=108)

89

-8.3

-9.7, -6.9

-6.8

-8.8, -4.8

<0.0001

Placebo (N=109)

95

-1.5

-2.9, -0.1

Change from baseline in ambulatory night-time average DBP (mmHg) at Week 12

(LS Means)

Baxdrostat 2 mg (N=108)

89

-7.9

-9.6, -6.3

-6.9

-9.1, -4.6

<0.0001

Placebo (N=109)

95

-1.1

-2.7, 0.5

Change from baseline in ambulatory daytime average DBP (mmHg) at Week 12

(LS Means)

Baxdrostat 2 mg (N=108)

89

-8.4

-9.9, -6.9

-6.7

-8.8, -4.6

<0.0001

Placebo (N=109)

95

-1.7

-3.2, -0.3

Change from baseline in seated DBP (mmHg) at Week 12

(LS Means)

Baxdrostat 2 mg (N=108)

108

-7.6

-9.5, -5.7

-5.0

-7.7, -2.3

0.0003

Placebo (N=109)

109

-2.6

-4.5, -0.7

Achieving a nocturnal SBP dipping of >= 10% at Week 12

(Odds ratio)

Baxdrostat 2 mg (N=108)

89

36 (40.4%)

NA

1.6

0.9, 3.0

0.1458

Placebo (N=109)

95

28 (29.5%)

NA

*The main analyses of ambulatory BP endpoints include patients with valid ambulatory blood pressure monitoring at both baseline and Week 12, without imputation of missing data.

LS, least squares; n Number of subjects in analysis; N Number of subjects per treatment group

Notes

Hard-to-control hypertension

Hypertension is a medical condition characterized by consistently high blood pressure levels, affecting an estimated 1.4 billion people worldwide.6,21,22 Over time, this can damage blood vessels and vital organs, increasing the risk of serious health problems such as heart attack, stroke, heart failure and kidney disease.20,21 An observational study of nearly 60,000 patients studied over a median of 9.7 years showed that a 9.5 mmHg increase in 24-hour ambulatory SBP was associated with a 30% increase in risk of all-cause mortality and 41% increase in risk of cardiovascular death.4 Studies have shown that increased night-time blood pressure is associated with higher cardiovascular risk,8,11 and patients with hypertension have a higher risk of cardiovascular events like heart attack, stroke and death around the time of their morning blood pressure surge.2,3

Hard-to-control (uncontrolled and resistant) hypertension remains a major public health challenge.23 Despite lifestyle changes and the use of multiple medications, approximately 50% of patients in the US who are being treated for hypertension still do not have their blood pressure under control.7 Uncontrolled hypertension refers to persistently elevated blood pressure despite the use of two or more medications, while resistant hypertension, a more severe form, remains elevated despite treatment with three or more medications.7,21 Guidelines currently recommend that in patients with hypertension, treated BP values should be targeted to 130/80 mmHg or lower in most patients.21,22

A key contributor to hard-to-control hypertension is aldosterone, a hormone that raises blood pressure by promoting sodium and water retention.24,25 Elevated aldosterone levels, along with factors such as obesity, high salt intake, and various genetic or secondary conditions,26 are strongly associated with poor blood pressure control. When left untreated, hypertension significantly increases the risk of cardiovascular and kidney-related complications.21,22

Bax24 trial

The Phase III Bax24 trial16 is a randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of 2mg baxdrostat versus placebo, administered once a day (QD) orally, on the reduction of ambulatory SBP, as well as safety and tolerability in participants with resistant hypertension. A total of 218 patients were randomized in a 1:1 ratio to receive baxdrostat 2mg or placebo once daily during a 12-week double blind period. The primary efficacy endpoint was the change from baseline in ambulatory 24-hour average SBP at Week 12.

Additional secondary endpoints include the effect of baxdrostat versus placebo on change from baseline in ambulatory night-time average SBP, change from baseline in ambulatory daytime average SBP, change from baseline in seated SBP, the number of participants achieving ambulatory 24-hour average SBP of less than 130 mmHg , change from baseline in ambulatory 24-hour average diastolic blood pressure (DBP), change from baseline in ambulatory night-time average DBP, change from baseline in the average ambulatory daytime average DBP, change from baseline on seated DBP and the number of participants achieving a nocturnal SBP dipping of greater than or equal to 10%, all measured at Week 12. Occurrence of adverse events was evaluated during the 12-week treatment period as well as during a 2-week safety follow-up period.

Baxdrostat

Baxdrostat is a potential first-in-class, highly selective and potent, oral, small molecule that inhibits aldosterone synthase,12 an enzyme encoded by the CYP11B2 gene, which is responsible for the synthesis of aldosterone in the adrenal gland.24 In clinical trials, baxdrostat was observed to significantly lower aldosterone levels without affecting cortisol levels across a wide range of doses.13,27 Baxdrostat is currently being investigated in clinical trials as a monotherapy for hypertension13-16 and primary aldosteronism,17 and in combination with dapagliflozin for chronic kidney disease and hypertension,18,19 and the prevention of heart failure in high-risk patients.20

AstraZeneca acquired baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023.28

AstraZeneca in CVRM

Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company’s ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow the Company on social media @AstraZeneca.

References

Williams B, et al. Effect of baxdrostat on 24-hour ambulatory blood pressure in patients with resistant hypertension: the Bax24 trial. Presented at: American Heart Association Scientific Sessions 2025; November 7–10, 2025; New Orleans, LA.

Renna NF, et al. Morning blood pressure surge as a predictor of cardiovascular events in patients with hypertension. Blood Press Monit. 2023;28(3):149-157

Kario K et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res. 2006;29(8):581-7.

Staplin N, et al. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet. 2023;401(10393):2041-2050.

Flack JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025. Aug 30:10.1056/NEJMoa2507109. doi: 10.1056/NEJMoa2507109.

World Health Organization. Global report on hypertension 2025: high stakes: turning evidence into action. 2025. https://iris.who.int/handle/10665/382841. Accessed September 2025.

Carey RM, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431.

Narita K, et al. Nighttime Home Blood Pressure Is Associated With the Cardiovascular Disease Events Risk in Treatment-Resistant Hypertension. Hypertension. 2022;79(2):e18-e20

Kario K, et al. Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis. Circulation. 2020;142(19):1810-1820

Williams B, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018;39(33):3021-3104.

Niiranen TJ, Mäki J, Puukka P, Karanko H, Jula AM. Office, home, and ambulatory blood pressures as predictors of cardiovascular risk. Hypertension. 2014 Aug;64(2):281-6.

Bogman K, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69(1):189-196.

Freeman MW, et al. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023;46(1):108-118.

ClinicalTrials.gov.A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (BaxHTN). Available at: https://clinicaltrials.gov/study/NCT06034743. Accessed October 2025.

ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (BaxAsia). Available at: https://clinicaltrials.gov/study/NCT06344104. Accessed October 2025.

ClinicalTrials.gov. A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension (Bax24). Available at: https://clinicaltrials.gov/study/NCT06168409. Accessed October 2025.

ClinicalTrials.gov. A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism (BaxPA). Available at: https://clinicaltrials.gov/study/NCT07007793. Accessed October 2025.

ClinicalTrials.gov. A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. Available at: https://clinicaltrials.gov/study/NCT06268873. Accessed October 2025.

ClinicalTrials.gov. A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific). Available at: https://clinicaltrials.gov/study/NCT06742723. Accessed October 2025.

ClinicalTrials.gov. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (Prevent-HF). Available at: https://clinicaltrials.gov/study/NCT06677060. Accessed October 2025.

McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018.

Jones DW, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2025;152:e114–e218.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980.

Cannavo A, et al. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid Med Cell Longev. 2018;2018:1204598.

Inoue K, et al. Serum aldosterone concentration, blood pressure, and coronary artery calcium: The multi-ethnic study of atherosclerosis. Hypertension. 2020;76(1):113-120.

van Oort S, et al. Association of cardiovascular risk factors and lifestyle behaviors with hypertension: a mendelian randomization study. Hypertension. 2020;76(6):1971-1979.

Freeman MW, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395-405.

AstraZeneca 2023. Acquisition of CinCor Pharma complete. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset.html. Accessed October 2025.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. 

Oslo, Norway, 9 November 2025

Reference is made to the stock exchange announcements published on 6 November 2025 and 7 November 2025 (the “Announcements”) by Ensurge Micropower ASA ("Ensurge" or the "Company") regarding a contemplated private placement (the "Private Placement") of new shares in the Company (the "Offer Shares”).

The Private Placement has been successfully placed, raising gross proceeds to the Company of NOK 100 million, through the allocation of 83,678,032 Offer Shares in Tranche 1 (as defined below) and conditional allocation of 27,433,079 Offer Shares in Tranche 2 (as defined below) each at a subscription price of NOK 0.90 per Offer Share (the "Subscription Price").

The net proceeds to the Company from the Private Placement will be used (i) to expand the team in order to develop the product in partnership with paying customers, drive manufacturing and operational robustness for high-quality product launch into high-volume applications, and build external relationships with paying customers and other third parties, (ii) to upgrade certain capital equipment, including material handling and manufacturing processes, for high-quality repeatable manufacturing, and (iii) for general corporate purpose to attract higher volume external suppliers and maintain negotiating leverage vis-à-vis external third parties.

The following primary insiders (and closely associated companies) were allocated a total of 5,858,184 Offer Shares in the private placement for a total amount of NOK 5,272,365.60:

Shauna McIntyre, the Company's CEO, currently owning no shares and votes, has been allocated 113,666 Offer Shares, for a total subscription amount of approx. USD 10,000.Lars Eikeland, the Company's CFO, currently owning approximately 0.56% of the Company's shares and votes, has been allocated 1,311,185 Offer Shares, for a total subscription amount of approx. EUR 100,000.AS Mascot Holding (closely associated company to Alexander Munch-Thore, the Chairperson of the Board, currently owning no shares and votes) has been allocated 1,000,000 Offer Shares, for a total subscription amount of NOK 900,000.Nina Riibe, Board member, currently owning no shares and votes, has been allocated 100,000 Offer Shares, for a total subscription amount of NOK 90,000.Coretech AS (closely associated company to Thomas Ramm, Board member, currently owning approximately 0.40% of the Company's shares and votes) has been allocated 3,333,333 Offer Shares, for a total subscription amount of NOK 3 million. The Private Placement consists of two tranches, whereof the 83,678,032 Offer Shares in Tranche 1 have been issued pursuant to the 10% authorization to issue new shares (the "Board Authorization") granted to the Company’s board of directors (the “Board”) by the extraordinary general meeting on 8 August 2025 ("Tranche 1"). The second tranche consists of 27,433,079 Offer Shares and is conditional on approval by an extraordinary general meeting expected to be held on or about 2 December 2025 (“EGM”) of the Company ("Tranche 2").

Settlement of Offer Shares in Tranche 1 is expected to take place on or about 12 November 2025, and settlement of Offer Shares in Tranche 2 is expected to take place on or about 4 December 2025, subject to approval by the EGM. Delivery-versus-payment ("DVP") settlement will be facilitated with existing and unencumbered shares in the Company that are already admitted to trading on Euronext Oslo Børs based on a share lending from Mirabella Financial Services LLP, on behalf of Svelland Global Trading Master Fund and certain other accounts. The share loans will be settled with new shares in the Company issued by the Board pursuant to the Board Authorization (Tranche 1) and the EGM (Tranche 2). Listing of Offer Shares in excess of 17,964,329 Offer Shares requires publication of a listing prospectus (the "Prospectus") as approved by the Financial Supervisory Authority of Norway. Such excess shares will be redelivered to the share lenders on a separate ISIN and will only become tradeable on Euronext Oslo Børs once the Prospectus has been approved and published, which is expected on or about 2 December 2025.

Notification of allotment of the Offer Shares and payment instructions are expected to be issued to the applicants on or about 10 November 2025 through a notification to be issued by the Managers.

The Offer Shares allocated to applicants in Tranche 1 will be tradable from notification of allocation, and the Offer Shares allocated to applicants in Tranche 2 will be tradable subject to the EGM resolution to issue the Tranche 2 shares. Completion of Tranche 1 is not conditional upon completion of Tranche 2. The settlement of Offer Shares under Tranche 1 will remain final and binding and cannot be revoked, cancelled or terminated by the respective applicants if Tranche 2 is not completed. The Company reserves the right in its sole discretion to cancel Tranche 2 if the relevant Conditions (set out in the Announcements) are not fulfilled. If Tranche 2 is not completed (e.g. due to non-approval by the EGM), applicants will not be delivered Offer Shares in Tranche 2, and the Company will only receive the gross proceeds for the issue of the Offer Shares issued in Tranche 1. 

The Board has resolved the share capital increase in relation to Tranche 1 and following registration of the share capital increase with the Norwegian Register of Business Enterprises (the "NRBE"), the Company will have a share capital of NOK 470,981,655.50 divided into 941,963,311 shares, each with a nominal value of NOK 0.50. Further, following and subject to registration of the share capital increase in Tranche 2 (subject to resolution by the EGM) with the NRBE, the Company will have a share capital of NOK 484,698,195 divided into 969,396,390 shares, each with a nominal value of NOK 0.50.

The Private Placement represents a deviation from the shareholders' pre-emptive right to subscribe for the Offer Shares. The Board considered the Private Placement in light of the equal treatment obligations under the Public Limited Liability Companies Act and Norwegian Securities Trading Act and deemed the Private Placement to be in compliance with these requirements. The Board holds the view that it is in the common interest of the Company and its shareholders to raise equity through a private placement, in light of the current market conditions and the funding alternatives currently available to the Company. The Private Placement has enabled the Company to raise capital in an efficient manner, and it has been structured to ensure that a market-based subscription price was achieved. On this basis, the Board has considered the proposed transaction structure and the Private Placement to be in the common interest of the Company and its shareholders. However, to limit the dilutive effect of the Private Placement and to facilitate equal treatment, the Board will consider to carry out a subsequent offering directed towards shareholders who did not participate in the Private Placement (see details below).

Potential Subsequent Offering

The Board will propose that the EGM resolves to provide the Board with an authorization to conduct a subsequent offering of new shares in the Company to be carried out at a subscription price per share equal to the Subscription Price in the Private Placement (the "Subsequent Offering"). The maximum amount of the Subsequent Offering would be NOK 20,000,000. The Subsequent Offering would be subject to among other things (i) completion of the Private Placement, (ii) relevant corporate resolutions, including approval by the Board and the EGM, (iii) the prevailing market price of Ensurge's shares being higher than the Subscription Price, and (iv) approval of the Prospectus. A Subsequent Offering would be directed towards existing shareholders in the Company as of 7 November 2025, as registered in Ensurge's register of shareholders with Euronext Securities Oslo, the central securities depositary in Norway (Nw. Verdipapirsentralen) (the "VPS") two trading days thereafter, who (i) were not allocated Offer Shares in the Private Placement and (ii) are not resident in a jurisdiction where such offering would be unlawful or would (in jurisdictions other than Norway) require any prospectus, filing, registration or similar action (the "Eligible Shareholders"). The Eligible Shareholders are expected to be granted non-tradable allocation rights. If carried out, the subscription period in a Subsequent Offering is expected to commence shortly after approval and publication of the Prospectus, and the subscription price in the Subsequent Offering will be the same as the Subscription Price in the Private Placement. Ensurge will issue a separate stock exchange notice with the key information relating to the Subsequent Offering. The Company reserves the right in its sole discretion to not conduct or to cancel the Subsequent Offering and will, if and when finally resolved, issue a separate stock exchange notice with further details on the Subsequent Offering.

Advisors
Arctic Securities AS and DNB Carnegie, a part of DNB Bank ASA are acting as managers and joint bookrunners in connection with the Private Placement. Ræder Bing Advokatfirma AS is acting as the Company's legal advisor. Advokatfirmaet Thommessen AS is acting as legal advisors to the Managers.

For more information, please contact:
Shauna McIntyre - Chief Executive Officer 
E- mail: [email protected]

This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17 and section 5 -12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Ståle Bjørnstad, VP, Corporate Development and IR, on 9 November 2025 at the time and date stated above in this announcement.

About Ensurge Micropower 
Ensurge (www.ensurge.com) powers the future of AI-enabled devices with advanced microbattery technology that delivers unmatched performance and safety. From its base in San Jose, California, the Company's team of battery specialists have pioneered thin-film batteries produced on high-precision roll-to-roll production processes. These innovations enable new possibilities in form-factor-constrained applications across consumer, medical, and industrial markets. Ensurge partners with leading global customers to accelerate their products to market and is listed on the Oslo Stock Exchange. For more news and information on Ensurge, please visit https://www.ensurge.com/news-room.

Important information: 
This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. 

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or its securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to "qualified institutional buyers" as defined in Rule 144A under the Securities Act. 

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "EU Prospectus Regulation" means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State. 

This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. 

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements, inter alia in relation to the Private Placement and the Offer Shares, in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. 

Actual events may differ significantly from any anticipated development due to a number of factors, including without limitation, changes in investment levels and need for the Company's services, changes in the general economic, political and market conditions in the markets in which the Company operate, the Company's ability to attract, retain and motivate qualified personnel, changes in the Company's ability to engage in commercially acceptable acquisitions and strategic investments, and changes in laws and regulation and the potential impact of legal proceedings and actions. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not provide any guarantees that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this document. 

The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement. 

Neither the Managers nor any of their affiliates make any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein. 

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. Neither the Managers nor any of their affiliates accept any liability arising from the use of this announcement. 

Massachusetts-based Essex Investment Management disclosed a new position in Globalstar (GSAT +4.62%), valued at approximately $7.1 million, according to an SEC filing on Thursday.

What HappenedAccording to a filing with the Securities and Exchange Commission released Thursday, Essex Investment Management reported establishing a new position in Globalstar (GSAT +4.62%) during the third quarter. The fund added 194,343 shares with an estimated market value of $7.1 million based on the quarter-end price. Globalstar now represents 1.1% of Essex's $653.4 million in reportable U.S. equity holdings.

What Else to KnowTop five holdings after the filing:

NASDAQ:KTOS: $22.3 million (3.4% of AUM)NASDAQ:STRL: $15.5 million (2.4% of AUM)NASDAQ:AMSC: $14.6 million (2.2% of AUM)NASDAQ:TSEM: $14.2 million (2.2% of AUM)NASDAQ:INSM: $12.5 million (1.9% of AUM)As of Friday's market close, Globalstar shares were priced at $50.48, up 82% over the past year and well outperforming the S&P 500's 12% gain in the same period.

Company OverviewMetricValuePrice (as of market close Friday)$50.48Market Capitalization$6.4 billionRevenue (TTM)$260.7 millionNet Income (TTM)($38.4 million)Company SnapshotGlobalstar, Inc. is a leading provider of mobile satellite communications, enabling connectivity in remote and underserved regions worldwide. The company leverages its proprietary satellite network to deliver mission-critical voice, data, and IoT solutions to enterprise and government clients, as well as individual consumers.

With a strategic focus on expanding its 5G capabilities and commercializing Band n53 spectrum, Globalstar aims to strengthen its competitive position in the evolving telecommunications landscape. Its diversified product suite and global reach underpin its role as a key player in satellite-enabled communications and asset tracking.

Foolish TakeEssex Investment Management’s new Globalstar position comes amid growing institutional interest in satellite communications and connectivity, and for Essex, the addition fits the firm's small- and micro-cap growth strategy, which targets companies at “inflection points” of technological acceleration.

The disclosure also coincided with Globalstar’s third-quarter earnings release, which reported record third-quarter revenue of $73.8 million, up from $72.3 million a year earlier, driven by strong wholesale capacity services and subscriber equipment sales. While net income fell to $1.1 million due to higher non-cash interest and foreign currency impacts, the company reaffirmed full-year guidance between $260 million and $285 million in revenue and a 50% adjusted EBITDA margin. CEO Paul Jacobs highlighted progress on its next-generation C-3 satellite system and expansion of its global ground infrastructure, underscoring Globalstar’s ambition to be a hybrid satellite-terrestrial network provider.

For long-term investors, Globalstar’s growing partnerships and improved commercialization could represent a durable growth runway—but near-term volatility remains a risk as the company continues investing heavily in infrastructure expansion and technology integration.

Glossary13F reportable assets under management: The portion of a fund’s holdings required to be disclosed quarterly to the SEC.
Alpha: A measure of an investment’s performance relative to a benchmark, showing value added or lost by active management.
Assets under management (AUM): The total market value of investments managed on behalf of clients by a financial institution or fund.
Band n53 spectrum: A specific frequency band allocated for wireless communications, used to support advanced mobile and 5G services.
Gateway operators: Companies or entities that manage ground stations connecting satellite networks to terrestrial telecommunications systems.
Mobile satellite services: Communication services delivered via satellites, enabling voice, data, and tracking in remote or mobile environments.
Mission-critical: Essential systems or services whose failure would significantly disrupt operations or safety.
IoT (Internet of Things): A network of physical devices embedded with sensors and software to connect and exchange data over the internet.
TTM: The 12-month period ending with the most recent quarterly report.

The stock market's most influential company just got hit with its biggest weekly sell-off since April.

Nvidia (NVDA +0.04%) stock got hit with one of its biggest pullbacks this year over the last week of trading. The company's share price closed out the week down 7.1%. Meanwhile, the S&P 500's level declined 1.6%, and the Nasdaq Composite's level declined 3%.

Nvidia stock had been down as much as 11.6% on the week prior to seeing some substantial recovery momentum late in Friday's trading. While the company's share price has recently seen a valuation pullback, it's still up 40% year to date.

Image source: Nvidia.

Nvidia stock slips amid valuation concerns and Michael Burry's bearish bet
Some top analysts and investment banks have recently been raising the alarm regarding valuations for artificial intelligence (AI), and the past week saw AI-bubble concerns play a big role in shaping valuation for companies concentrated in the space and the broader market. Adding to the bearish momentum for Nvidia, Scion Asset Management disclosed that it had purchased put options with an approximate notional value of $187 million on Nvidia stock.

Scion Asset Management is led by Michael Burry, who is one of the most high-profile investors in the world today. As the central player behind the 2008-financial-crash-era short trades that were the basis for The Big Short book and its film adaptation, bearish bets from Burry can carry a lot of weight on Wall Street.

Today's Change

(

0.04

%) $

0.07

Current Price

$

188.15

Can Nvidia's valuation defy a rise in bearish macroeconomic indicators?
In addition to increased caution about AI valuations, some bearish macroeconomic news prompted pullbacks across the broader market this week. Challenger, Gray & Christmas published a report on Thursday showing that U.S. companies had laid off over 153,000 employees in October -- marking the highest monthly level of layoffs in 22 years. The next day, the University of Michigan released its November update measuring consumer confidence in the country and published data showing that the tracking index had weakened to its weakest level since 2022.

Thanks to hopes that Democrats and Republicans could soon reach terms on a spending deal that would bring an end to the government shutdown, Nvidia stock was able to recover from big sell-offs early in Friday's trading. For better or worse, it's likely that macroeconomic news will play a big role in shaping the AI leader's valuation over the next year.

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial.

November 09, 2025 5:06 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Synopsys, Inc. (NASDAQ: SNPS) securities between December 4, 2024 and September 9, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 30, 2025.

SO WHAT: If you purchased Synopsys securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Synopsys class action, go to https://rosenlegal.com/submit-form/?case_id=44981 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 30, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) the extent to which Synopsys' increased focus on artificial intelligence customers, which require additional customization, was deteriorating the economics of its Design IP business; (2) that, as a result, "certain road map and resource decisions" were unlikely to "yield their intended results,"; (3) that the foregoing had a material negative impact on financial results; and (4) as a result of the foregoing, defendants' positive statements about Synopsys' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Synopsys class action, go to https://rosenlegal.com/submit-form/?case_id=44981 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273707

By

PYMNTS
 | 
November 9, 2025

 | 

Meta will invest $600 billion in the United States by 2028 to build artificial intelligence (AI) data centers.

“As the importance of AI grows, so will the importance of data centers,” the company said in a Friday (Nov. 7) press release. “We’ll continue to build and scale infrastructure for the future of AI while supporting the communities that host us.”

Meta told investors during an Oct. 29 earnings call that it would be stepping up its infrastructure spending as it races to build what CEO Mark Zuckerberg calls “personal superintelligence.”

Chief Financial Officer Susan Li said the company expects capital-expenditure dollar growth to be “notably larger in 2026 than 2025” and total expenses to grow at a “significantly faster” rate next year.

The biggest driver of those expenses will be compute — both company-owned data centers and third-party cloud services — followed by compensation for AI talent, Li said.

During the same earning call, Zuckerberg said of the investment: “We keep on seeing this pattern where we build some amount of infrastructure to what we think is an aggressive assumption, and then we keep on having more demand to be able to use more compute. So, I think that suggests that being able to make a significantly larger investment here is very likely to be a profitable thing over some period.”

Advertisement: Scroll to Continue

It was reported Wednesday (Nov. 5) that Meta investors were “losing patience” with the company’s AI spending, remembering the spending on the metaverse that sent the firm’s shares tumbling.

While the company’s most recent earnings exceeded expectations, investors were concerned about its capital expenditures.

Tiffany Wade, senior portfolio manager at Columbia Threadneedle Investments, told Bloomberg: “This feels like a return to Meta’s old days of overspending on things that are frivolous or which don’t have appropriate return demands tied to them. Investors are losing patience.”

It was reported Thursday (Nov. 6) that companies’ investments in projects related to AI are expected to fuel the debt issuance market through next year.

U.S. investment-grade bond issuance could reach $1.7 trillion this year and $1.85 trillion in 2026, driven in part by blue-chip companies borrowing more to fund their AI investments, Maureen O’Connor, global head of high-grade debt syndicate at Wells Fargo, told Bloomberg TV.

These two names have doubled the Nasdaq Composite in 2025.

This has been an amazing year for tech stocks. The sector is the biggest in the S&P 500 and is having an outsize year, growing 22% so far in 2025. And there's lots of momentum for that to continue.

Investors love tech stocks because of their raw potential. They represent companies that are changing the world. Companies that manufacture semiconductors, software, infrastructure, and electronics are all helping to push the envelope, bringing about innovations that the finance, energy, and consumer goods sectors utilize.

Image source: Getty Images.

Semiconductors in particular are a massive investing opportunity. The global semiconductor market is expected to grow from $583.38 billion this year to $1.29 trillion by 2030, according to Statista, for a compound annual growth rate of 10.24%.

If you have $5,000 to invest in the tech sector, I've got two semiconductor names that should be on your buy list. One of them is a stock that's been on a record-setting run and appears destined for even greater gains. The other is an exchange-traded fund (ETF) that is heavily weighted with high-flying semiconductor stocks.

Both give you an outstanding chance to build wealth.

Stock choice: Nvidia
I don't like gambling with my money. And while nothing is ever certain in the stock market, Nvidia (NVDA +0.03%) looks to be as close to a sure thing as you can find.

Nvidia's mammoth run began in 2023 when the market realized how critical the company's graphics processing units (GPUs) would be to the future of artificial intelligence (AI). GPUs power high-performance computing tasks, such as the training of large language models, AI platforms, machine learning, and data analytics. An investment of $10,000 on Jan. 1, 2023, would have turned into $130,000 at this point.

CEO Jensen Huang bragged at the company's GTC D.C. conference last month that "our GPUs are everywhere," and he's absolutely right. As Nvidia announced deals with South Korean companies Samsung and Hyundai, the presidential office in Seoul announced that more than 260,000 of Nvidia GPUs will be deployed in the country.

Today's Change

(

0.03

%) $

0.05

Current Price

$

188.13

Nvidia also just announced a $1.15 billion partnership with the telecommunications company Deutsche Tekekom to build out AI capabilities in Europe, including powering a Munich data center with up to 10,000 Nvidia Blackwell GPUs.

Nvidia's revenue in the second quarter of fiscal 2026 (ended July 27, 2025) was $46.7 billion, with $41.1 billion of that coming from data centers. Nvidia's revenue was up 56% on a year-over-year basis, and I'm expecting even better numbers when it reports earnings again on Nov. 19.

Fund choice: VanEck Semiconductor ETF
It's never a good idea to put all your eggs in one basket. That's why I like ETFs, because they allow you the opportunity to stay laser-focused on a specific sector, like semiconductors, while also diversifying into several companies at the same time.

The VanEck Semiconductor ETF (SMH 0.85%) is a small ETF, holding only 25 companies, including Nvidia as the most heavily weighted stock.

Company

Weighting

Nvidia

18.31%

Taiwan Semiconductor Manufacturing

9.38%

Broadcom

8.08%

Advanced Micro Devices

6.68%

Micron Technology

6.35%

Lam Research

5.75%

Applied Materials

5.52%

ASML

5.47%

Intel

5.47%

Kla

4.48%

Qualcomm

4.23%

But it has some Nvidia competitors, too. And importantly, it also has some other important names, like Taiwan Semiconductor Manufacturing (TSMC), which is the largest chip manufacturer in the world. It also has ASML Holding and Lam Research, which make critical components that allow fabricators like TSMC to produce the chips.

The fund, which tracks the MVIS US Listed Semiconductor 25 Index, includes companies that generate at least half of their revenue from semiconductors or semiconductor equipment. The SMH ETF started its dramatic rise in the last several quarters as semiconductor sales took off, with a $10,000 investment three years ago being worth more than $38,000 now. The fund has an expense ratio of 0.35%, or $35 annually for each $10,000 invested.

Today's Change

(

-0.85

%) $

-2.97

Current Price

$

348.12

How to invest $5,000
For these picks, I would put $2,500 into each name. True, you get a heavy exposure to Nvidia because it also carries the heaviest weight in the SMH ETF, but that's how confident I am in Nvidia at this point in its growth story.

Both of these names are generating better than 45% returns in 2025, which is twice the gain that you'd see from the tech-heavy Nasdaq Composite. That's a significant reward for investing in the hard-charging semiconductor industry today.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.

So what: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Baxter class action, go to https://rosenlegal.com/submit-form/?case_id=17664 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants misled investors by failing to disclose that: (1) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (2) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (3) Baxter's attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (4) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (5) based on the foregoing, Baxter's statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Baxter class action, go to https://rosenlegal.com/submit-form/?case_id=17664  call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

November 09, 2025 6:19 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS" or "ADSs") of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased WPP ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of WPP's media arm; notably, that it was not truly equipped to handle the ongoing macroeconomic challenges while competing effectively and had instead begun to lose significant market share to its competitors. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273687

Darius Baruo
Nov 09, 2025 20:23

Avalanche (AVAX) trades at $17.84, up 3% after Beetz gaming platform featured the token, while technical analysis reveals neutral momentum amid broader crypto market stability.

Quick Take
• AVAX trading at $17.84 (up 3.0% in 24h)
• Beetz gaming platform features Avalanche in daily challenge, enhancing crypto gaming visibility
• Price testing resistance near 20-day moving average at $18.47
• Following Bitcoin's positive momentum in absence of major fundamental catalysts

Market Events Driving Avalanche Price Movement
Trading on technical factors and modest positive sentiment following gaming sector recognition. The most notable recent development came from Beetz, a popular Telegram-based crypto gaming platform, which featured Avalanche in its "Answer the Oracle" daily challenge on November 8th. Participants who correctly identified AVAX as Avalanche's native token received 4,000 tokens as rewards.

While this gaming platform integration represents positive ecosystem development, the event had limited direct impact on AVAX price movements. The modest 3% daily gain appears more correlated with broader cryptocurrency market stability and Bitcoin's recent strength rather than this specific adoption milestone.

No significant institutional announcements, partnership developments, or regulatory changes have emerged in the past 48 hours. The current price action reflects technical positioning as traders navigate between key moving average levels in a relatively quiet news environment.

AVAX Technical Analysis: Neutral Consolidation Phase
Price Action Context
AVAX price currently sits just below its 20-day moving average at $18.47, having recovered from recent lows near the $16.81 support level. The token remains significantly below its 50-day ($23.67) and 200-day ($22.95) moving averages, indicating the longer-term downtrend remains intact despite today's modest gains.

Trading volume on Binance spot markets reached $40.3 million over 24 hours, representing moderate but not exceptional institutional interest. The price action suggests consolidation within the established range rather than a decisive directional break.

Key Technical Indicators
The RSI reading of 40.98 positions Avalanche in neutral territory, neither oversold nor overbought, providing room for movement in either direction. The MACD histogram shows a slight bullish divergence at 0.2267, though the overall MACD remains negative at -1.6599, suggesting any upward momentum remains tentative.

Avalanche technical analysis reveals the token trading within its Bollinger Bands, with current positioning at 38.3% of the band width, indicating neither extreme buying nor selling pressure.

Critical Price Levels for Avalanche Traders
Immediate Levels (24-48 hours)
• Resistance: $18.47 (20-day moving average acting as key technical barrier)
• Support: $17.00 (psychological level and recent consolidation floor)

Breakout/Breakdown Scenarios
A break below $17.00 support could trigger further selling toward the $15.77 lower Bollinger Band and potentially test the $15.00 major support level. Conversely, clearing the $18.47 resistance would target the $21.10 immediate resistance zone, though the stronger resistance at $21.18 (upper Bollinger Band) represents a more significant technical hurdle.

AVAX Correlation Analysis
Bitcoin's positive performance today has provided modest tailwinds for AVAX price, though Avalanche continues to underperform relative to the broader market leader. The correlation remains positive but weaker than typical during strong trending periods.

Traditional market stability, with equity markets showing resilience, has contributed to the neutral-to-positive sentiment across risk assets including cryptocurrencies. However, AVAX has not demonstrated significant sensitivity to traditional market movements in recent sessions.

Trading Outlook: Avalanche Near-Term Prospects
Bullish Case
A sustained break above $18.47 with increasing volume could target the $21.10-$21.18 resistance cluster. Gaming sector adoption momentum, if accompanied by additional platform integrations, might provide fundamental support for higher valuations.

Bearish Case
Failure to reclaim the 20-day moving average may signal continued consolidation or potential downside toward $15.00 support. The significant gap between current price and longer-term moving averages suggests vulnerability to broader market weakness.

Risk Management
Conservative traders should consider stops below $16.80 to limit downside exposure, while aggressive positions might use $17.00 as a stop level. Given the daily ATR of $1.66, position sizing should account for normal volatility expectations around these key levels.

Image source: Shutterstock

avax price analysis
avax price prediction

With XRP now sitting at $2.30 to $2.31 over the last hour, marking a modest 1.6% gain for the day, the coin sports a market capitalization of $138 billion and a 24-hour trading volume of $2.48 billion. A tightly wound intraday range between $2.25 and $2.33 hints at caution beneath the surface sparkle.

Alvin Lang
Nov 09, 2025 20:40

BCH price holds above $500 psychological support at $503.80, up 2.5% daily, as technical indicators suggest consolidation phase ahead of potential directional move.

Quick Take
• BCH trading at $503.80 (up 2.5% in 24h)
• No significant news catalysts driving current price action
• Testing critical support confluence near $500 psychological level
• Following broader crypto market sentiment with Bitcoin correlation

Market Events Driving Bitcoin Cash Price Movement
Bitcoin Cash is trading on technical factors in the absence of major catalysts, with no significant news events impacting BCH price movement over the past week. The current 2.5% daily gain appears driven by broader cryptocurrency market sentiment rather than Bitcoin Cash-specific developments.

The BCH price action reflects typical weekend consolidation patterns seen across digital assets, with trading volume at $14.5 million on Binance spot markets indicating moderate institutional interest. Without major news catalysts, traders are focusing on technical levels and correlation patterns with Bitcoin and traditional risk assets.

BCH Technical Analysis: Consolidation Phase
Price Action Context
Bitcoin Cash technical analysis reveals a consolidation pattern, with BCH price currently trading below most key moving averages. The current $503.80 level sits just above the 200-day SMA at $504.35, creating a critical support confluence that has attracted buying interest over the past 24 hours.

The coin is trading significantly below its 20-day ($515.05) and 50-day ($535.09) moving averages, suggesting the medium-term trend remains under pressure despite today's modest gains. Volume patterns indicate cautious institutional participation rather than aggressive accumulation.

Key Technical Indicators
The RSI reading of 46.61 places Bitcoin Cash in neutral territory, providing room for movement in either direction without immediate overbought or oversold conditions. The MACD histogram showing -1.63 indicates bearish momentum remains intact, though the negative reading has been diminishing over recent sessions.

Bollinger Bands analysis shows BCH price positioning at 0.41 within the bands, suggesting the asset is trading in the lower half of its recent range but not approaching oversold extremes. The daily ATR of $33.98 indicates elevated volatility that traders should factor into position sizing decisions.

Critical Price Levels for Bitcoin Cash Traders
Immediate Levels (24-48 hours)
• Resistance: $515.05 (20-day moving average confluence)
• Support: $500.00 (psychological level and 200-day MA cluster)

Breakout/Breakdown Scenarios
A break below the $500 support zone could trigger selling toward the $460.30 level, representing the next significant support cluster. Conversely, reclaiming the $515 resistance would target the $535 area where the 50-day moving average provides additional overhead pressure.

BCH Correlation Analysis
Bitcoin Cash continues showing strong correlation with Bitcoin's price movements, following the broader cryptocurrency market's mixed signals today. The correlation remains particularly evident during low-volume weekend sessions when algorithmic trading drives much of the price action.

Traditional market correlation appears muted in current conditions, with Bitcoin Cash technical analysis suggesting the asset is primarily responding to crypto-specific sentiment rather than broader risk asset movements. This independence from traditional markets could provide opportunities for crypto-focused strategies.

Trading Outlook: Bitcoin Cash Near-Term Prospects
Bullish Case
A sustained hold above $500 support combined with Bitcoin strength could drive BCH price toward the $535-540 resistance cluster. Volume expansion above $20 million would signal increased institutional interest and support higher price targets.

Bearish Case
Failure to hold $500 support risks accelerated selling toward $460, especially if Bitcoin experiences weakness. The bearish MACD configuration suggests momentum sellers remain in control of medium-term direction.

Risk Management
Conservative traders should consider stops below $495 to limit downside exposure, while position sizing should account for the elevated $34 daily volatility range. The current technical setup favors range-bound strategies over directional bets until clearer momentum emerges.

Image source: Shutterstock

bch price analysis
bch price prediction

Nov 09, 2025 at 19:50 // Price

Litecoin (LTC) has not risen since moving above the moving average lines. The cryptocurrency climbed above these lines but encountered resistance

The cryptocurrency climbed above these lines but encountered resistance around $110. After reaching this recent high, it fell below the 50-day SMA.

Litecoin price long-term prediction: bullish

On the downside, selling pressure is expected to persist above the 21-day SMA support, or the $95 low. If bears push the price below the moving average lines, negative momentum could drive it down to $80.

Currently, Litecoin is trading below the 50-day SMA support and above the 21-day SMA support. When the moving average lines are breached, the altcoin tends to establish a new trend. Litecoin is now valued at $100.27.

Technical Indicators 

Resistance Levels: $100, $120, $140

Support Levels: $60, $40, $20 

Litecoin indicator analysis

The price bars are positioned above the horizontal moving average lines. However, bears are attempting to push the price below the 50-day SMA. If they succeed, Litecoin's price could decline significantly. On the 4-hour chart, the price bars remain above the horizontal moving average.

What is the next move for Litecoin?

Litecoin's price is rising while maintaining a sideways trend. There are long candlestick wicks at several price levels, indicating significant selling pressure at recent highs. Currently, the cryptocurrency is declining as it returns to its previous price range above $80.

Disclaimer. This analysis and forecast are the personal opinions of the author. The data provided is collected by the author and is not sponsored by any company or token developer. This is not a recommendation to buy or sell cryptocurrency and should not be viewed as an endorsement by Coinidol.com. Readers should do their research before investing in funds.

XRP has spent the past week on the continuation of a downtrend from the previous week, slipping from above $2.50 before rebounding around $2.12 and now hovering around $2.30. The price action reflects a market struggling to find direction, caught between bullish optimism and lingering selling pressure.

Despite the broader slowdown in its price action, technical analysis shows that XRP is still displaying a resilient structure on the charts that maintains its critical support levels. According to Egrag Crypto, a popular analyst known for his long-term technical outlooks on XRP, the token may soon enter what will become the most explosive fifth wave yet.

XRP Elliott Wave Analysis: ‘The Power Of 5’
Egrag Crypto’s latest technical analysis on the social media platform X points to the fact that XRP is in the final stages of its fourth impulse wave, which is a corrective wave based on the popular Elliott Wave Theory. Notably, this movement is now setting up for the beginning of the fifth wave, which is a bullish impulse under the same theory.

Looking at previous cycles on the 5-day candlestick timeframe chart, particularly during 2017 and 2021, showed that similar setups came before massive upward surges in XRP’s price. The analyst’s chart displays a repeating structure of five-wave patterns, each representing major bullish impulses in the token’s history. 

The chart also reflects the distinct cyclical rhythm of XRP’s price behavior over the years. Each major impulsive phase (waves 1, 3, and 5) has always been followed by smaller corrective waves (2 and 4), a structure that continues to repeat with precision. 

XRP is currently trading at $2.27. Chart: TradingView
The overlapping bands in cyan and pink, representing exponential moving averages, now point to XRP consolidating within a strong support region around $2.20, which indicates that the fourth impulse wave is coming to an end.

XRP Technical Analysis: Source @egragcrypto on X

Analyst Says Don’t Fight It
By Egrag Crypto’s measure, the ongoing consolidation might be setting the stage for a similar move to double-digit prices if the fifth wave unfolds as projected.

The visual projection marks potential Fibonacci extensions of 1.272, 1.414, 1.618, and 2.618 at $4.789, $5.515, $6.755, and $18.259 as possible long-term targets once the fifth wave takes hold. These levels may act as resistance points in the impending bull phase because they resemble the wave geometry that drove XRP’s earlier rallies in 2017 and 2021.

Interestingly, the analyst also referenced how skepticism often peaks before major rallies. He reminded followers of a trader who lost $30 million shorting XRP during its last major uptrend in 2024. As such, the analyst concluded by urging traders not to “fight the fifth wave” but to “ride it.” 

At the time of writing, XRP is trading at $2.27, down by 1.6% and 9.2% in the past 24 hours and seven days, respectively. 

Featured image from Unsplash, chart from TradingView

Crypto‑treasury stocks, which rallied when companies stuffed their balance sheets with Bitcoin and ether, are sinking after recent price drops. For much of the year, investors were selling shares or borrowing funds to buy crypto, betting that corporate treasuries loaded with tokens would outperform holding the coins directly.

In a groundbreaking move for decentralized finance, Beep has officially launched on the Sui blockchain, unveiling what it calls the world's first agentic wallet and finance protocol. The initiative blends artificial intelligence (AI) with DeFi infrastructure, introducing a new era of AI-driven financial automation, zero-fee payments, and real-time transactions across global markets.

2 hours ago

Large, long-term crypto and Bitcoin investors continue to sell into the market, keeping asset prices from hitting a blow-off top.

1395

Crypto whales and long-term holders are cashing out, exerting constant selling pressure on markets, and keeping crypto prices suppressed, similar to market dynamics following the 2000s dot-com stock market crash, according to analyst Jordi Visser.

Visser said the current price action in the crypto market is reminiscent of the period following the 2000 dot-com stock market bubble, which crashed stocks by up to 80%, followed by 16 years of consolidation before they regained their previous highs.

This meant that venture capitalists, who invested in tech during the crash, were forced to hold their investments due to mandated lock-up periods as they treaded water and then desperately sold into the markets as soon as they were able to, Visser said. He added:

“Many stocks were trading below their IPO prices. We have a similar situation going on right now. VC and insider investors, desperate for liquidity or redemption, sold into every rally. That's what's happened to me for Solana, Ethereum, for every altcoin, and for Bitcoin.”The US stock market took about 16 years to recover to its previous all-time high and was suppressed by large investors selling into the market. Source: Jordi VisserVisser clarified that it would not take 16 years for crypto prices to rebound, but was using the 2000s dot-com aftermath to illustrate the sell-side pressure dynamics at play, and said crypto is nearing the end of this consolidation phase, with a maximum of 1 year left.

Has Bitcoin bottomed out around the $100,000 level?The price of BTC shows signs of bottoming out around $100,000, according to some analysts, but others fear a potential drop to $92,000 if selling pressure continues to mount.

Whales and long-term holders typically cash in at all-time highs, and whale selling is not a problem in and of itself, CryptoQuant analyst Julio Moreno said.

Long-term BTC holders are now dumping their coins onto the market faster than the market can absorb the supply. Source: Julio MorenoThe sell-side pressure from whales and long-term holders only suppresses asset prices if new demand is not there to soak up the BTC supply being dumped on the markets.

“Since October, long-term holder selling has increased; nothing new here, but demand is contracting, unable to absorb long-term holder supply at a higher price,” Moreno said.

Magazine: Altcoin season 2025 is almost here… but the rules have changed

On Sunday, privacy coins put on a show as zcash (ZEC) leapt 12.8% to crack the $640 mark, while monero ( XMR) sprinted 21% to sail past $440 per coin. Privacy tokens are clearly basking in the spotlight right now—and the crowd's loving it.